These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32859609)

  • 1. Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian
    Notz Q; Meybohm P; Kranke P; Weismann D; Lotz C; Schmalzing M
    Ann Rheum Dis; 2022 Nov; 81(11):e216. PubMed ID: 32859609
    [No Abstract]   [Full Text] [Related]  

  • 2. Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian
    Mathian A; Amoura Z
    Ann Rheum Dis; 2022 Nov; 81(11):e217. PubMed ID: 33239273
    [No Abstract]   [Full Text] [Related]  

  • 3. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'.
    Nikpour M; Teh B; Wicks IP; Pellegrini M
    Ann Rheum Dis; 2021 Mar; 80(3):e33. PubMed ID: 32471898
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon
    Konig MF; Gianfrancesco M; Yazdany J; Robinson PC
    Ann Rheum Dis; 2021 Apr; 80(4):e55. PubMed ID: 32475834
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to: 'Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Mar; 80(3):e34. PubMed ID: 32471900
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics.
    Mendel A; Bernatsky S; Askanase A; Bae SC; Clarke AE; Costedoat-Chalumeau N; Gladman DD; Gordon C; Hanly J; Jacobsen S; Kalunian K; Mak A; Mosca M; Pons-Estel BA; Ruiz-Irastorza G; Urowitz M; Vinet É
    Ann Rheum Dis; 2021 Feb; 80(2):1-2. PubMed ID: 32586918
    [No Abstract]   [Full Text] [Related]  

  • 7. Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 May; 80(5):e70. PubMed ID: 32737109
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.
    Carbillon L; Benbara A; Boujenah J
    Ann Rheum Dis; 2021 Apr; 80(4):e54. PubMed ID: 32475831
    [No Abstract]   [Full Text] [Related]  

  • 9. Relapsed hydroxychloroquine induced thrombocytopenia in a systemic lupus erythematosus patient.
    Antón Vázquez V; Pascual L; Corominas H; Giménez Torrecilla I
    Reumatol Clin; 2017; 13(5):294-296. PubMed ID: 27263963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxychloroquine shortages during the COVID-19 pandemic.
    Mendel A; Bernatsky S; Thorne JC; Lacaille D; Johnson SR; Vinet É
    Ann Rheum Dis; 2021 Mar; 80(3):e31. PubMed ID: 32434820
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review.
    He F; Luo Q; Lei M; Fan L; Shao X; Hu K; Qin S; Yu N; Cao J; Yang L
    Clin Rheumatol; 2020 Sep; 39(9):2803-2810. PubMed ID: 32725351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
    Chiricozzi A; Garcovich S; Malvaso D; Giovanardi G; Peris K
    Int J Dermatol; 2020 Nov; 59(11):1423-1424. PubMed ID: 32966593
    [No Abstract]   [Full Text] [Related]  

  • 13. Hydroxychloroquine and COVID-19: can we learn from the use of rituximab in systemic lupus erythematosus?
    Lekpa FK; Ngahane BHM; Njonnou SRS; Fouda H; Halle MP; Njankouo YM; Dzudie A; Choukem SP; Luma HN
    Pan Afr Med J; 2021; 38():372. PubMed ID: 34367451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxychloroquine blood assay as a marker of nonadherence in patients with systemic lupus erythematosus: comment on the article by Koneru et al.
    Costedoat-Chalumeau N; Amoura Z; Marra D; Piette JC
    Arthritis Rheum; 2008 Jan; 59(1):153; author reply 153-4. PubMed ID: 18163410
    [No Abstract]   [Full Text] [Related]  

  • 15. Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment?
    Costedoat-Chalumeau N; Leroux G; Piette JC; Amoura Z
    Joint Bone Spine; 2010 Jan; 77(1):4-5. PubMed ID: 20022788
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 10. Hydroxychloroquine].
    Yokogawa N
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2960-5. PubMed ID: 22175138
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxychloroquine and lupus flare: a good drug, but we need to do better.
    Crow MK; Kirou KA
    Ann Rheum Dis; 2022 Mar; 81(3):303-305. PubMed ID: 35039325
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel use of rituximab in macrophage activation syndrome secondary to systemic lupus erythematosus.
    Junga Z; Stitt R; Tracy C; Keith M
    BMJ Case Rep; 2017 Aug; 2017():. PubMed ID: 28827301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments.
    Gendebien Z; von Frenckell C; Ribbens C; André B; Thys M; Gangolf M; Seidel L; Malaise MG; Malaise O
    Ann Rheum Dis; 2021 Jun; 80(6):e94. PubMed ID: 32586921
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß
    Mathian A; Amoura Z
    Ann Rheum Dis; 2021 Apr; 80(4):e53. PubMed ID: 32616603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.